TY - JOUR
T1 - Neurexin 1 (NRXN1) splice isoform expression during human neocortical development and aging
AU - Jenkins, A. K.
AU - Paterson, C.
AU - Wang, Y.
AU - Hyde, T. M.
AU - Kleinman, J. E.
AU - Law, A. J.
N1 - Funding Information:
This research was supported primarily by funds from the National Institutes of Health, National Institute of Mental Health intramural program to the Law lab and Clinical Brain Disorders Branch, and in part by NIH, R01MH103716 (Law PI). We would like to acknowledge Dr Daniel Weinberger, for additional research support from the Clinical Brain Disorders Branch and Amy Deep-Soboslay of the National Institutes of Health, National Institute of Mental Health and Lieber Institute for Brain Development for efforts in demographic characterization.
Publisher Copyright:
© 2016 Macmillan Publishers Limited.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Neurexin 1 (NRXN1), a presynaptic cell adhesion molecule, is implicated in several neurodevelopmental disorders characterized by synaptic dysfunction including autism, intellectual disability and schizophrenia. To gain insight into NRXN1's involvement in human cortical development we used quantitative real-time PCR to examine the expression trajectories of NRXN1, and its predominant isoforms, NRXN1-α and NRXN1-β, in prefrontal cortex from fetal stages to aging. In addition, we investigated whether prefrontal cortical expression levels of NRXN1 transcripts are altered in schizophrenia or bipolar disorder in comparison with non-psychiatric control subjects. We observed that all three NRXN1 transcripts were highly expressed during human fetal cortical development, markedly increasing with gestational age. In the postnatal dorsolateral prefrontal cortex, expression levels were negatively correlated with age, peaking at birth until ∼3 years of age, after which levels declined markedly to be stable across the lifespan. NRXN1-β expression was modestly but significantly elevated in the brains of patients with schizophrenia compared with non-psychiatric controls, whereas NRXN1-α expression was increased in bipolar disorder. These data provide novel evidence that NRXN1 expression is highest in human dorsolateral prefrontal cortex during critical developmental windows relevant to the onset and diagnosis of a range of neurodevelopmental disorders, and that NRXN1 expression may be differentially altered in neuropsychiatric disorders.
AB - Neurexin 1 (NRXN1), a presynaptic cell adhesion molecule, is implicated in several neurodevelopmental disorders characterized by synaptic dysfunction including autism, intellectual disability and schizophrenia. To gain insight into NRXN1's involvement in human cortical development we used quantitative real-time PCR to examine the expression trajectories of NRXN1, and its predominant isoforms, NRXN1-α and NRXN1-β, in prefrontal cortex from fetal stages to aging. In addition, we investigated whether prefrontal cortical expression levels of NRXN1 transcripts are altered in schizophrenia or bipolar disorder in comparison with non-psychiatric control subjects. We observed that all three NRXN1 transcripts were highly expressed during human fetal cortical development, markedly increasing with gestational age. In the postnatal dorsolateral prefrontal cortex, expression levels were negatively correlated with age, peaking at birth until ∼3 years of age, after which levels declined markedly to be stable across the lifespan. NRXN1-β expression was modestly but significantly elevated in the brains of patients with schizophrenia compared with non-psychiatric controls, whereas NRXN1-α expression was increased in bipolar disorder. These data provide novel evidence that NRXN1 expression is highest in human dorsolateral prefrontal cortex during critical developmental windows relevant to the onset and diagnosis of a range of neurodevelopmental disorders, and that NRXN1 expression may be differentially altered in neuropsychiatric disorders.
UR - http://www.scopus.com/inward/record.url?scp=84937916250&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937916250&partnerID=8YFLogxK
U2 - 10.1038/mp.2015.107
DO - 10.1038/mp.2015.107
M3 - Article
C2 - 26216298
AN - SCOPUS:84937916250
SN - 1359-4184
VL - 21
SP - 701
EP - 706
JO - Molecular psychiatry
JF - Molecular psychiatry
IS - 5
ER -